Profile data is unavailable for this security.
About the company
N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.
- Revenue in GBP (TTM)1.95k
- Net income in GBP-1.28m
- Incorporated1979
- Employees5.00
- LocationN4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
- Phone+44 133 269 0061
- Fax+44 127 982 1300
- Websitehttps://www.n4pharma.com/
Mergers & acquisitions
| Acquired company | N4P:LSE since announced | Transaction value |
|---|---|---|
| Nanogenic Solutions Ltd | -42.86% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Voyager Life PLC | 314.00k | -1.10m | 630.13k | 28.00 | -- | 0.9933 | -- | 2.01 | -0.0912 | -0.0912 | 0.0253 | 0.044 | 0.1897 | 1.58 | 3.85 | 11,214.29 | -66.51 | -- | -77.02 | -- | 41.72 | -- | -350.64 | -- | 2.83 | -69.50 | 0.4625 | -- | 59.55 | -- | -38.70 | -- | -- | -- |
| Ovoca Bio PLC | 0.00 | -2.01m | 672.21k | 5.00 | -- | 0.1546 | -- | -- | -0.0246 | -0.0246 | 0.00 | 0.0533 | 0.00 | -- | -- | 0.00 | -27.00 | -17.82 | -32.86 | -19.39 | -- | -- | -- | -- | 4.68 | -48.64 | 0.00 | -- | -- | -- | -6.96 | -- | -- | -- |
| Nuformix PLC | 0.00 | -436.95k | 1.52m | 2.00 | -- | 0.3282 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 1.63m | 7.00 | -- | 0.7388 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| N4 Pharma PLC | 1.95k | -1.28m | 2.15m | 5.00 | -- | 1.91 | -- | 1,102.69 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 2.63m | 25.00 | -- | 3.32 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| TheraCryf PLC | 838.00k | -3.35m | 3.21m | 7.00 | -- | 0.5239 | -- | 3.82 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.24m | 50.00 | -- | 1.39 | -- | 2.05 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| IXICO PLC | 6.67m | -1.18m | 3.57m | 89.00 | -- | 0.3119 | -- | 0.535 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ValiRx Plc | 0.00 | -2.41m | 4.04m | 8.00 | -- | 0.7423 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 4.91m | 4.00 | -- | 1.01 | -- | 379.33 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
